guest ::
| Home > Publications database > Epstein-Barr virus lytic replication and cancer. > print |
| 001 | 296014 | ||
| 005 | 20250102091312.0 | ||
| 024 | 7 | _ | |a 10.1016/j.coviro.2024.101438 |2 doi |
| 024 | 7 | _ | |a pmid:39700641 |2 pmid |
| 024 | 7 | _ | |a 1879-6257 |2 ISSN |
| 024 | 7 | _ | |a 1879-6265 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2024-02757 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Li, Hao |0 P:(DE-He78)5b422df679d8af3361c421d51f9420ed |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Epstein-Barr virus lytic replication and cancer. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2025 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1735805569_23499 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:D400#LA:D400# |
| 520 | _ | _ | |a Epidemiological studies have provided strong evidence that Epstein-Barr virus (EBV) lytic replication is linked to cancer development. Evidence of abortive lytic replication in some tumors and infections with recombinant viruses incapable of lytic replication in animal models have reinforced this view. Furthermore, multiple lytic proteins have been shown to induce genetic instability, a well-characterized precancerous state. In particular, lytic proteins dysregulated the DNA damage response, interfered with cell cycle progression, and induced the development of structural genetic abnormalities. However, there is so far no direct evidence from in vivo or in vitro studies that lytic replication alone can induce cancer. Here, we critically review the currently available evidence that EBV lytic replication contributes to cancer development and suggest future research directions. |
| 536 | _ | _ | |a 314 - Immunologie und Krebs (POF4-314) |0 G:(DE-HGF)POF4-314 |c POF4-314 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 700 | 1 | _ | |a Lee, Chih-Ying |0 P:(DE-He78)ea25dbd9617667864c867bab0b1142db |b 1 |e First author |u dkfz |
| 700 | 1 | _ | |a Delecluse, Henri-Jacques |0 P:(DE-He78)25d3c74b949988c637571e696fc04b25 |b 2 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1016/j.coviro.2024.101438 |g Vol. 70, p. 101438 - |0 PERI:(DE-600)2611378-8 |p 101438 |t Current opinion in virology |v 70 |y 2025 |x 1879-6257 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:296014 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)5b422df679d8af3361c421d51f9420ed |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)ea25dbd9617667864c867bab0b1142db |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)25d3c74b949988c637571e696fc04b25 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-314 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Immunologie und Krebs |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-08-26 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-08-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1120 |2 StatID |b BIOSIS Reviews Reports And Meetings |d 2023-08-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-08-26 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CURR OPIN VIROL : 2022 |d 2023-08-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-26 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b CURR OPIN VIROL : 2022 |d 2023-08-26 |
| 920 | 2 | _ | |0 I:(DE-He78)D400-20160331 |k D400 |l Pathologie infektionsbedingter Tumoren |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)D400-20160331 |k D400 |l Pathologie infektionsbedingter Tumoren |x 0 |
| 920 | 0 | _ | |0 I:(DE-He78)D400-20160331 |k D400 |l Pathologie infektionsbedingter Tumoren |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)D400-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|